

PHARMACY / MEDICAL POLICY – 5.01.635

Pharmacologic Treatment of Epidermolysis Bullosa

BCBSA Ref. Policy: 5.01.47

Effective Date: Dec. 1, 2025

Last Revised: Jan. 1, 2026


Replaces: N/A

RELATED MEDICAL POLICIES:

N/A

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

Introduction

Epidermolysis Bullosa (EB) is a collection of rare genetic disorders that affect the fragility of the skin. These disorders are characterized by abnormal structures that disrupt either the junction between the dermis and epidermis or the basal layer of the epidermis itself. As a result, the skin becomes more susceptible to damage from physical pressure. Common signs of EB include the formation of blisters, erosion of the skin, the presence of nonhealing ulcers, and the development of scars after minor injuries. EB is classified into four major categories, such as, epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB) and kindler epidermolysis bullosa (KEB).

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Drug	Medical Necessity
<p>Filsuvez (birch triterpenes) topical</p>	<p>Filsuvez (birch triterpenes) may be considered medically necessary for the treatment of dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) when all the following criteria are met:</p> <ul style="list-style-type: none"> • The individual is aged 6 months or older <p>AND</p> <ul style="list-style-type: none"> • Has been diagnosed with DEB or JEB confirmed by genetic testing <p>AND</p> <ul style="list-style-type: none"> • Has had at least one open wound associated with DEB or JEB for at least 21 days that will be treated with Filsuvez (birch triterpenes) <p>AND</p> <ul style="list-style-type: none"> • Filsuvez (birch triterpenes) will not be used concurrently with Vyjuvek (beremagene geperpavec-svdt) or Zevaskyn (prademagene zamikeracel) <p>AND</p> <ul style="list-style-type: none"> • Filsuvez (birch triterpenes) will not be used on wounds treated with Zevaskyn (prademagene zamikeracel) <p>AND</p> <ul style="list-style-type: none"> • Filsuvez (birch triterpenes) is prescribed by or in consultation with a dermatologist or medical geneticist <p>AND</p> <ul style="list-style-type: none"> • Filsuvez (birch triterpenes) will be limited to 1 application per wound per day
<p>Vyjuvek (beremagene geperpavec-svdt) topical</p>	<p>Vyjuvek (beremagene geperpavec-svdt) may be considered medically necessary in individuals with dystrophic epidermolysis bullosa when all the following criteria are met:</p> <ul style="list-style-type: none"> • The individual has a confirmed diagnosis of dystrophic epidermolysis bullosa <p>AND</p> <ul style="list-style-type: none"> • Has documentation showing mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene <p>AND</p> <ul style="list-style-type: none"> • Confirmed negative pregnancy status <p>AND</p>



Drug	Medical Necessity
	<ul style="list-style-type: none"> • Does not have a current or history of squamous cell carcinoma in the wound <p>AND</p> <ul style="list-style-type: none"> • Vyjuvek (beremagene geperpavec-svdt) will not be used concurrently with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel) <p>AND</p> <ul style="list-style-type: none"> • Vyjuvek (beremagene geperpavec-svdt) will not be used on wounds treated with Zevaskyn (prademagene zamikeracel) <p>AND</p> <ul style="list-style-type: none"> • Use is prescribed by or in consultation with a dermatologist or medical geneticist <p>AND</p> <ul style="list-style-type: none"> • The maximum weekly dose prescribed is based on the age of the individual: <ul style="list-style-type: none"> ○ 2×10^9 PFU (1 mL) for individuals less than 3 years old ○ 4×10^9 PFU (2 mL) for individuals 3 years and older <p>*Note: PFU = Plaque forming units. Maximum weekly volume is the volume after mixing Vyjuvek suspension with excipient gel</p>
<p>Zevaskyn (prademagene zamikeracel) topical</p>	<p>Zevaskyn (prademagene zamikeracel) may be considered medically necessary for the treatment of wounds in adult and pediatric individuals with recessive dystrophic epidermolysis bullosa (RDEB) when all the following criteria are met:</p> <ul style="list-style-type: none"> • The individual has a diagnosis of RDEB confirmed by genetic testing showing a pathogenic variant in both alleles in the <i>collagen type VII alpha 1 chain (COL7A1)</i> gene <p>AND</p> <ul style="list-style-type: none"> • Has cutaneous wound(s) which are adequate for treatment (e.g., stage 2 wounds that have an area of at least 20 cm²) and have been present for at least 3 months <p>AND</p> <ul style="list-style-type: none"> • Confirmed negative pregnancy status <p>AND</p> <ul style="list-style-type: none"> • Does not have a current or history of squamous cell carcinoma in the wound



Drug	Medical Necessity
	<p>AND</p> <ul style="list-style-type: none"> Zevaskyn (prademagene zamikeracel) will not be used concurrently with Filsuvez (birch triterpenes) or Vyjuvek (beremagene geperpavec-svdt) <p>AND</p> <ul style="list-style-type: none"> Use is prescribed by or in consultation with a dermatologist or medical geneticist <p>AND</p> <ul style="list-style-type: none"> Zevaskyn (prademagene zamikeracel) will be applied by a healthcare provider <p>AND</p> <ul style="list-style-type: none"> Requires treatment of new expansion of pre-existing wounds, new wounds, or open wounds

Drug	Investigational
<ul style="list-style-type: none"> Filsuvez (birch triterpenes) Vyjuvek (beremagene geperpavec-svdt) Zevaskyn (prademagene zamikeracel) 	<p>Zevaskyn (prademagene zamikeracel) is intended as a one-time treatment per area. Re-treatment of wounds that were previously treated with Zevaskyn (prademagene zamikeracel) is considered investigational.</p> <p>The medications listed in this policy are subject to the product’s US Food and Drug Administration (FDA) dosage and administration prescribing information.</p> <p>All other uses of Filsuvez (birch triterpenes), Vyjuvek (beremagene geperpavec-svdt), and Zevaskyn (prademagene zamikeracel) for conditions not outlined in this policy are considered investigational.</p>

Length of Approval	
Approval	Criteria
Initial authorization	Non-formulary exception reviews for Filsuvez (birch triterpenes), Vyjuvek (beremagene geperpavec-svdt), and Zevaskyn (prademagene zamikeracel) may be approved for up to 12 months.



Length of Approval	
Approval	Criteria
	<p>All other reviews for Filsuvez (birch triterpenes) and Vyjuvek (beremagene geperpavec-svdt) may be approved for up to 6 months.</p> <p>All other reviews for Zevaskyn (prademagene zamikeracel) may be approved for up to 6 months as a one-time application per wound.</p>
Re-authorization criteria	<p>Non-formulary exception reviews for Filsuvez (birch triterpenes) and Vyjuvek (beremagene geperpavec-svdt) may be approved for up to 12 months as long as the drug-specific coverage criteria are met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</p> <p>All other reviews for Filsuvez (birch triterpenes) and Vyjuvek (beremagene geperpavec-svdt) may be approved for 6 months as long as the drug-specific coverage criteria are met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</p> <p>Non-formulary exception reviews for Zevaskyn (prademagene zamikeracel) may be approved for up to 12 months and all other reviews for Zevaskyn (prademagene zamikeracel) may be approved for up to 6 months for continued treatment of new expansion of pre-existing wounds, new wounds, or open wounds. Re-authorization of re-treatment of wounds that were previously treated with Zevaskyn (prademagene zamikeracel) is considered investigational.</p>

Documentation Requirements
<p>The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:</p> <ul style="list-style-type: none"> Office visit notes that contain the diagnosis, relevant history, physical evaluation, and medication history.



Coding

Code	Description
HCPCS	
J3389	Topical administration, prademagene zamikeracel, per treatment (new code effective 01/01/26)
J3401	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10 ⁹ PFU/ml vector genomes (Vyjuvek), per 0.1 ml
J3490	Unclassified drugs (use to report: Filsuvez)
J3590	Unclassified biologics (use to report: Zevaskyn)

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Consideration of Age

Age limits specified in this policy are determined according to FDA-approved indications where applicable.

Benefit Application

Filsuvez (birch triterpenes) is managed under the pharmacy and medical benefit. Vyjuvek (beremagene geperpavec-svdt) and Zevaskyn (prademagene zamikeracel) are managed under the medical benefit.

Evidence Review



Dystrophic Epidermolysis Bullosa Background

Dystrophic Epidermolysis Bullosa (DEB) is a prominent subgroup within the category of conditions known as epidermolysis bullosa (EB). DEB is characterized by formation of blisters on the skin and mucosal membranes, which subsequently heal but leave behind scar tissue. The underlying cause of DEB is attributed to mutations occurring in the COL7A1 gene. This gene encodes the alpha-1 chain of type VII collagen. Collagen VII is the primary component of the anchoring fibrils situated beneath the lamina densa of the epidermal basement membrane zone. DEB manifests in four major subtypes, along with several rare, dominant, or recessive variations. The clinical features commonly observed in DEB include skin fragility, blister formation, scarring, nail abnormalities, and the development of milia in areas where blisters have healed. The therapeutic approach for DEB includes supportive care. These includes the wound care to promote healing, effective infection control measures to prevent and manage infections, strategies to address and treat complications that may arise, and provision of nutritional support to ensure optimal nourishment for the individual.

Vyjuvek (beremagene geperpavec-svdt)

Vyjuvek is a non-integrating gene therapy that employs a genetically modified, replication-deficient, herpes-simplex virus type 1 vector. It is indicated for the treatment of wounds in individuals 6 months of age and older with dystrophic epidermolysis bullosa with mutation in the collagen type VII alpha 1 chain (COL7A1) gene. Vyjuvek has the ability to transduce both keratinocytes and fibroblasts. Upon cellular entry, the vector genome is delivered to the nucleus, initiating the transcription of the human COL7A1 gene. The resulting transcripts enable the production and secretion of mature COL7 protein by cell. These COL7 molecules self-assemble into elongated, slender bundles known as anchoring fibrils. Anchoring fibrils play a vital role in maintaining the cohesion between the epidermis and dermis, thereby ensuring the integrity of the skin.

Vyjuvek is formulated as a biological suspension combined with an excipient gel for topical application. The recommended dose of Vyjuvek is determined based on the individual's age. For individuals aged between six months and less than three years old, the maximum weekly recommended dose is 1.6×10^9 plaque-forming units (PFU). For individuals aged three years and older, the maximum weekly recommended dose is 3.2×10^9 PFU. The most common adverse reactions associated with Vyjuvek treatment include itching, chills, redness, rash, cough, and runny nose. There is currently no available data regarding the use of Vyjuvek in the pregnant women.



Evidence of Efficacy

The efficacy and safety of Vyjuvek was assessed in a phase 3, randomized, double-blind, intra-subject placebo-controlled trial. This trial included 31 individuals aged 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutations in the COL7A1 gene. Each participant had two comparable wounds selected based on the size, region, and appearance. These wounds were randomly assigned to receive either topical application of Vyjuvek or the placebo (excipient gel) once a week for 26 weeks.

In this trial the size of wounds treated with Vyjuvek gel ranged from 2 to 57 cm², with 74% of wounds measuring less than 20 cm². On the other hand, the size of the wound treated with placebo gel ranged from 2 to 52 cm², with 71% of wounds measuring less than 20 cm². The primary efficacy outcome was determined by the proportion of complete wound closure at 24 weeks, confirmed by two consecutive study visits spaced two weeks apart (at week 22 and 24 or at week 24 and 26). This outcome was compared between the wounds treated with Vyjuvek and the wounds treated with placebo gel. Complete wound closure was defined as the sustained closure of the wound observed at two consecutive visits two weeks apart. At the specified time points (week 22 and 24 or week 24 and 26), the proportion of wounds achieving complete closure in the Vyjuvek gel-treated group was 65%, whereas the proportion of complete closure in the placebo-treated group was 26%, resulting in a significant p-value of 0.012.

The secondary efficacy outcome assessed the proportion of complete wound closure at weeks 8 and 10, or at week 10 and 12, again comparing the treatment group and the placebo group. At the specified time points (week 8 and 10 or week 10 and 12), the proportion of wounds achieving complete closure in the Vyjuvek gel-treated group was 68%, whereas the proportion of complete closure in the placebo-treated group was 23%, resulting in a significant p-value of 0.003.

Filsuvez (birch triterpenes)

The Phase 3 EASE trial, which enrolled 223 individuals with epidermolysis bullosa (EB). Of those individuals treated with Filsuvez, 41.3% achieved complete target wound closure within 45 days compared with 28.9% in the placebo control group (P = 0.013). However, key secondary endpoints were not met, including complete wound closure at 90 days compared to placebo. During the trial, about 80% of individuals changed their wound dressings every 1 to 2 days, with every 2 days being somewhat more common than daily at Days 30, 60, and 90 of the double-



blind phase among individuals treated with Filsuvez. During the entire 90-day double-blind treatment period, separation in target wound closure occurred around Day 30 with the difference narrowing around Day 90. None of the secondary endpoints in the trial were met, except for a greater reduction in pain associated with dressing changes using the Wong Baker Faces scale in participants ≥ 4 years of age at Day 14 ($P = 0.022$). The difference between Filsuvez and vehicle were not statistically different for all other time points for which this outcome was measured, including at Day 90. Adverse events (AEs) occurred with similar frequency for Filsuvez (81.7%) compared with control gel (80.7%). AEs were predominantly of mild to moderate intensity (4.6% were severe). Any AEs leading to study withdrawal occurred in three individuals in the Filsuvez group and two individuals in the control group. One individual in the Filsuvez group and no individuals in the control group withdrew from the trial due to a serious AE that was deemed related to study treatment.

Zevaskyn (prademagene zamikeracel)

Zevaskyn (prademagene zamikeracel) consists of an individual's own skin cells (keratinocytes) that have been genetically modified, to produce functional type VII collagen. Zevaskyn COL7A1 gene-corrected cellular sheets are surgically applied to the individual's open wounds. In a single application, up to 12 approximately credit card-sized sheets can be joined together to cover large areas or applied to multiple distinct wounds. After Zevaskyn is prescribed and once payer approval is obtained, two 8-mm skin punch biopsies are collected from the individual in the outpatient setting of the qualified treatment center (QTC). The biopsies are shipped to Abeona's Cleveland, OH facility for manufacturing. The process from biopsy to applications is estimated to take approximately 25 days, according to Abeona. The individual's keratinocytes are genetically modified and grown into cellular sheets. Up to 12 sheets can be made from the biopsies, each covering an area of 41.25 cm² (5.5 cm \times 7.5 cm). When manufacturing is complete, the sheets are hand-delivered to the QTC by an Abeona Transport Specialist. Zevaskyn can only be administered by a qualified healthcare provider (HCP) at a QTC. Individuals must undergo general or other appropriate anesthesia for the surgical application. After the procedure, individuals are hospitalized for 5–10 days at the discretion of the physician to ensure wounds remain immobilized and undisturbed to allow for healing.

The efficacy of Zevaskyn for RDEB was evaluated in the Phase 3 VIITAL trial (NCT04227106), a multicenter, randomized, inpatient-controlled study that compared the application of Zevaskyn to standard-of-care (SOC) wound treatment in 11 individuals with RDEB. In total, 43 large, chronic wounds were treated with a single application of Zevaskyn and 43 matched control wounds were treated with SOC only. Both co-primary efficacy endpoints were met in the



VIITAL trial, demonstrating statistically significant healing of 50% or more from baseline in large chronic RDEB wounds, and pain reduction associated with wound dressing changes from baseline as assessed by the Wong-Baker FACES scale, as evaluated at 24 weeks after treatment.

Practice Guidelines and Position Statements

European Reference Network for Rare Skin Diseases

The European Reference Network for Rare and Undiagnosed Skin Diseases published expert consensus clinical position statements in 2021 regarding practical recommendations for the management of individuals suspected or diagnosed with epidermolysis bullosa covering diagnosis, wound management, oral care and treatment of pain and itch. They also published consensus clinical position recommendations in 2020 to aid decision-making and optimize clinical care by non-epidermolysis bullosa expert health professionals encountering emergency situations in babies, children and adults with epidermolysis bullosa. Both consensus statements were published prior to the Food and Drug Administration (FDA) approval beremagene geperpavec-svdt.

Dystrophic Epidermolysis Bullosa Research Association

International consensus best practice guidelines skin and wound care in epidermolysis bullosa were published in 2017. These guidelines were also published prior to the FDA approval beremagene geperpavec-svdt.

References

1. Martin L, Johann B, et al. Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features. Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features -UpToDate. Accessed February 12, 2025.
2. Krystal Biotech, Inc. Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB (GEM-3). Available at: Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB - Full Text View - <https://www.clinicaltrials.gov/ct2/show/NCT04491604>. Accessed February 12, 2025.
3. Vyjuvek (beremagene geperpavec-svdt) [package insert]. Pittsburgh, PA. Krystal Biotech, Inc. Revised September 2025.
4. Filsuvez (birch triterpenes) [package insert]. Wahlstedt Germany. Chiesi USA Inc. Revised May 2024.



5. Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. *Br J Dermatol*. Oct 2020; 183(4): 614-627. PMID 32017015
6. Tidman MJ, Eady RA. Evaluation of anchoring fibrils and other components of the dermal-epidermal junction in dystrophic epidermolysis bullosa by a quantitative ultrastructural technique. *J Invest Dermatol*. May 1985; 84(5): 374-7. PMID 4039741
7. Burgeson RE. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. *J Invest Dermatol*. Sep 1993; 101(3): 252-5. PMID 8370960
8. Dunnill MG, McGrath JA, Richards AJ, et al. Clinicopathological correlations of compound heterozygous COL7A1 mutations in recessive dystrophic epidermolysis bullosa. *J Invest Dermatol*. Aug 1996; 107(2): 171-7. PMID 8757758
9. Vahidnezhad H, Youssefian L, Zeinali S, et al. Dystrophic Epidermolysis Bullosa: COL7A1 Mutation Landscape in a Multi-Ethnic Cohort of 152 Extended Families with High Degree of Customary Consanguineous Marriages. *J Invest Dermatol*. Mar 2017; 137(3): 660-669. PMID 27899325
10. Fine JD. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry. *JAMA Dermatol*. Nov 01 2016; 152(11): 1231-1238. PMID 27463098
11. Food and Drug Administration (FDA). Guidance for Industry. Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment. June 2006; <https://www.fda.gov/media/71278/download>. Accessed February 12, 2025.
12. Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. *Nat Med*. Apr 2022; 28(4): 780-788. PMID 35347281
13. Guide SV, Gonzalez ME, Bağcı IS, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. *N Engl J Med*. Dec 15 2022; 387(24): 2211-2219. PMID 36516090
14. Mellerio JE, El Hachem M, Bellon N, et al. Emergency management in epidermolysis bullosa: consensus clinical recommendations from the European reference network for rare skin diseases. *Orphanet J Rare Dis*. Jun 06 2020; 15(1): 142. PMID 32505191
15. International consensus best practice guidelines skin and wound care in epidermolysis bullosa. Published 2017. Available at <https://www.debra-international.org/skin-and-wound-care-in-eb-cpg>. Accessed February 12, 2025.
16. Abeona Therapeutics, Inc. Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). <http://clinicaltrials.gov/study/NCT04227106>. Accessed June 2025.
17. Zevaskyn (prademagene zamikeracel) [package insert]. Cleveland, OH. Abeona Therapeutics Inc. Revised April 2025.

History

Date	Comments
07/01/23	New policy, approved June 13, 2023. Added coverage criteria for Vyjuvek for individuals 6 months of age and older with dystrophic epidermolysis bullosa with confirmed mutation in COL7A1 gene. Added HCPC code J3590 for Vyjuvek.
09/01/23	Interim Review, approved August 7, 2023. Updated Vyjuvek initial authorization and re-authorization time duration to 6 months.
01/01/24	Coding update. Added new HCPCS code J3401.



Date	Comments
07/01/24	Annual Review, approved June 11, 2024. Added coverage criteria for Filsuvez (birch triterpenes). Updated Vyjuvek (beremagene geperpavec-svdt) coverage criteria to indicate that the product is not used concurrently with Filsuvez (birch triterpenes).
03/01/25	Annual Review, approved February 24, 2025. Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months. Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information.
08/01/25	Interim Review, approved July 8, 2025. Added coverage for Zevaskyn (prademagene zamikeracel) for individuals aged 6 years and older with recessive dystrophic epidermolysis bullosa (RDEB) and confirmed mutation in COL7A1 gene. Updated Filsuvez (birch triterpenes) will not be used concurrently with Vyjuvek (beremagene geperpavec-svdt) or Zevaskyn (prademagene zamikeracel). Updated Vyjuvek (beremagene geperpavec-svdt) will not be used concurrently with Filsuvez (birch triterpenes) or Zevaskyn (prademagene zamikeracel). Added HCPCS code J3590 for Zevaskyn.
10/01/25	Interim Review, approved September 22, 2025. Updated Zevaskyn (prademagene zamikeracel) coverage criteria to remove the age requirement, clarified that RDEB is diagnosed by genetic testing showing a pathogenic variant in both alleles in the COL7A1 gene, and clarified that the individual has cutaneous wounds which are adequate for treatment (e.g., stage 2 wounds that have an area of at least 20 cm ²) and have been present for at least 3 months. Updated Zevaskyn (prademagene zamikeracel) coverage criteria to clarify that use is limited to new expansion of pre-existing wounds, new wounds, or open wounds. Updated Vyjuvek (beremagene geperpavec-svdt) and Filsuvez (birch triterpenes) coverage criteria to clarify that it will not be used on wounds treated with Zevaskyn.
11/01/25	Interim Review, approved October 14, 2025. Updated Vyjuvek (beremagene geperpavec-svdt) criteria by removing the age requirement and updating the maximum weekly dose based on age.
12/01/25	Interim Review, approved November 24, 2025. Updated Vyjuvek (beremagene geperpavec-svdt) criteria by removing healthcare provider administration requirement.
01/01/26	Coding update. Added new HCPCS code J3389 effective January 1, 2026.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2026 Premera All Rights Reserved.



Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

